<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545944</url>
  </required_header>
  <id_info>
    <org_study_id>VONO-101</org_study_id>
    <nct_id>NCT04545944</nct_id>
  </id_info>
  <brief_title>Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants</brief_title>
  <official_title>An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phathom Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phathom Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the time-dependent inhibition potential of repeated doses of oral vonoprazan on&#xD;
      the pharmacokinetics (PK) of a single oral dose of midazolam, a sensitive cytochrome P450 3A4&#xD;
      (CYP3A4) substrate, in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Actual">November 25, 2020</completion_date>
  <primary_completion_date type="Actual">November 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma midazolam concentration versus time curve from time 0 to the last quantifiable concentration (AUC0-t) following a single dose of midazolam administered alone and coadministered with multiple oral doses of vonoprazan</measure>
    <time_frame>From within 30 minutes prior to Day 1 midazolam dose up to 24 hours post dose (midazolam administered alone), and from within 30 minutes prior to Day 9 midazolam dose up to 48 hours post dose (midazolam coadministered with vonoprazan)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma midazolam concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf) following a single dose of midazolam administered alone and coadministered with multiple oral doses of vonoprazan</measure>
    <time_frame>From within 30 minutes prior to Day 1 midazolam dose up to 24 hours post dose (midazolam administered alone), and from within 30 minutes prior to Day 9 midazolam dose up to 48 hours post dose (midazolam coadministered with vonoprazan)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma midazolam concentration (Cmax) following a single dose of midazolam administered alone and coadministered with multiple oral doses of vonoprazan</measure>
    <time_frame>From within 30 minutes prior to Day 1 midazolam dose up to 24 hours post dose (midazolam administered alone), and from within 30 minutes prior to Day 9 midazolam dose up to 48 hours post dose (midazolam coadministered with vonoprazan)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Midazolam single doses / Vonoprazan multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>20 mg tablets administered orally</description>
    <arm_group_label>Midazolam single doses / Vonoprazan multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>2 mg syrup administered orally</description>
    <arm_group_label>Midazolam single doses / Vonoprazan multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participant is male or female 18 to 45 years of age, inclusive, at Screening.&#xD;
&#xD;
          2. The participant has a body mass index (BMI) 18 to 30 kg/m2, inclusive, and body weight&#xD;
             &gt;50 kg at Screening.&#xD;
&#xD;
          3. The participant is considered by the investigator to be in good general health as&#xD;
             determined by medical history, clinical laboratory test results, vital sign&#xD;
             measurements, 12-lead ECG results, and physical examination findings at Screening.&#xD;
&#xD;
          4. Female participants of childbearing potential who may be sexually active with a&#xD;
             non-sterilized male partner must use an acceptable method of birth control (ie,&#xD;
             diaphragm with spermicide, intrauterine device, condom with foam or vaginal&#xD;
             spermicide, oral contraceptives, or abstinence) from the signing of informed consent&#xD;
             until 4 weeks after the last dose of study drug or be surgically sterile (ie,&#xD;
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal&#xD;
             (defined as amenorrhea for 12 consecutive months and documented plasma&#xD;
             follicle-stimulating hormone [FSH] level &gt;40 IU/mL).&#xD;
&#xD;
          5. Female participants must have a negative pregnancy test at Screening and Check-in.&#xD;
&#xD;
          6. The participant agrees to comply with all protocol requirements.&#xD;
&#xD;
          7. The participant is able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The participant has a history of any clinically significant neurological,&#xD;
             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological,&#xD;
             hematological, or endocrine disease or other abnormality that may affect the ability&#xD;
             of the subject to participate in the study.&#xD;
&#xD;
          2. The participant has a positive test result for coronavirus disease 2019 (COVID-19),&#xD;
             hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency&#xD;
             virus type 1 or 2 antibodies at Screening.&#xD;
&#xD;
          3. The participant has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
             &gt;2 × the upper limit of normal (ULN) or total bilirubin &gt;1.5 × ULN (with the exception&#xD;
             of Gilbert's syndrome) at Screening or Check-in.&#xD;
&#xD;
          4. The participant has serum creatinine &gt;1.2 mg/dL or blood urea nitrogen &gt;20 mg/dL at&#xD;
             Screening or Check-in.&#xD;
&#xD;
          5. The participant has any acute laboratory abnormality at Screening that precludes&#xD;
             participation in the study, in the opinion of the investigator.&#xD;
&#xD;
          6. The participant has a current or chronic history of liver disease or known hepatic or&#xD;
             biliary abnormalities (with the exception of Gilbert's syndrome and asymptomatic&#xD;
             gallstones).&#xD;
&#xD;
          7. The subject has used any prescription (excluding hormonal birth control) or&#xD;
             over-the-counter medications (including CYP3A4 inducers) except paracetamol (up to 2 g&#xD;
             per day), including herbal or nutritional supplements, within 14 days (or 5&#xD;
             half-lives) before the first dose of study drug or throughout the study.&#xD;
&#xD;
          8. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville&#xD;
             orange-containing products (eg, marmalade), or food products that may be CYP3A4&#xD;
             inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress,&#xD;
             collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7&#xD;
             days (or 5 half-lives) before the first dose of study drug or throughout the study.&#xD;
&#xD;
          9. The subject has consumed caffeine or xanthine-containing products within 48 hours (or&#xD;
             5 half-lives) before the first dose of study drug or throughout the study.&#xD;
&#xD;
         10. The subject is a smoker or has used nicotine or nicotine-containing products (eg,&#xD;
             snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6&#xD;
             months before the first dose of study drug.&#xD;
&#xD;
         11. The subject has a history of alcohol abuse or drug addiction within the last year,&#xD;
             excessive alcohol consumption (regular alcohol intake &gt;21 units per week for male&#xD;
             subjects and &gt;14 units of alcohol per week for female subjects; 1 unit is equal to&#xD;
             approximately 1/2 pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure.&#xD;
&#xD;
         12. The subject has a positive test result for drugs of abuse, alcohol, or cotinine&#xD;
             (indicating active current smoking) at Screening or Check-in.&#xD;
&#xD;
         13. The subject is involved in strenuous activity or contact sports within 24 hours before&#xD;
             the first dose of study drug or throughout the study.&#xD;
&#xD;
         14. The subject has donated blood or blood products &gt;450 mL within 30 days before the&#xD;
             first dose of study drug.&#xD;
&#xD;
         15. The subject has a history of relevant drug and/or food allergies (ie, allergy to&#xD;
             midazolam, vonoprazan, or their excipients [including cherries] or any significant&#xD;
             food allergy that could preclude a standard diet in the clinical unit).&#xD;
&#xD;
         16. The subject has received study drug in another investigational study within 30 days of&#xD;
             dosing.&#xD;
&#xD;
         17. Female subject is pregnant or lactating, intends to become pregnant before, during, or&#xD;
             within 4 weeks after participating in this study, or intends to donate ova during this&#xD;
             time period.&#xD;
&#xD;
         18. The subject has a history of acute narrow-angle glaucoma.&#xD;
&#xD;
         19. In the opinion of the investigator, the subject is not suitable for entry into the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Phathom Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vonoprazan</keyword>
  <keyword>midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

